Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer

Author:

Oxley SamuelORCID,Ahmed Sarah,Baxter Kathryn,Blake DominicORCID,Braden Victoria,Brincat Mark R,Bryan Stacey,Dilley James,Dobbs Stephen,Durden AndrewORCID,Gomes Nana,Johnston Ben,Kaushik Sonali,Kokka Fani,Lockley Michelle,Lowe-Zinola JackORCID,Manchanda RanjitORCID,McCormick Aiste,Nott Charlotte,Owens Gemma Louise,Pandya Aayushi,Prince Jessica,Ryan Neil,Ryan Nicole,Sideris Michail,Tanna Sameera,Waters Justin,Zamesa Nathan,Thomas Mari,Olaitan Adeola

Abstract

ObjectiveTo determine the incidence of venous thromboembolism in patients with advanced epithelial ovarian cancer undergoing neoadjuvant chemotherapy in UK gynecological cancer centers. Secondary outcomes included incidence and timing of venous thromboembolism since cancer presentation, impact on cancer treatment, and mortality.MethodsAll UK gynecological cancer centers were invited to participate in this multi-center retrospective audit through the British Gynecological Cancer Society. Data were captured on all patients undergoing neoadjuvant chemotherapy for International Federation of Gynecology and Obstetrics (FIGO) stage III/IV epithelial ovarian cancer within a 12-month period during 2021–2022. Patients on anticoagulation prior to cancer presentation were excluded. Patients who were diagnosed with venous thromboembolism between cancer presentation and commencing neoadjuvant chemotherapy were also excluded from our analysis of venous thromboembolism rates from neoadjuvant chemotherapy.ResultsFourteen UK gynecological cancer centers returned data on 660 eligible patients. The median age was 67 years (range 34–96). In total, 131/660 (19.8%) patients were diagnosed with venous thromboembolism from cancer presentation until discharge following cytoreductive surgery. Between commencing neoadjuvant chemotherapy and post-operative discharge, 65/594 (10.9%) patients developed venous thromboembolism (median 11.3%, IQR 5.9–11.3); 55/594 (9.3%) during neoadjuvant chemotherapy, 10/594 (1.7%) during post-operative admission. There was no significant difference across centers (p=0.47). Of these 65 patients, 44 (68%) were diagnosed with pulmonary embolism and 30 (46%) with deep-vein thrombosis (nine had both), including in major abdominal/pelvic vessels, with 36 (55%) presenting symptomatically and 29 (45%) diagnosed incidentally on imaging. Venous thromboembolism resulted in mortality (n=3/65, 5%), and delays/changes/cancelation of treatment (n=18/65, 28%).ConclusionAcross a large, representative sample of UK gynecological cancer centers, one in five patients undergoing neoadjuvant chemotherapy were diagnosed with a potentially preventable venous thromboembolism, including one in nine diagnosed after commencing chemotherapy. This led to adverse clinical consequences for one third, including delay to oncological treatment and mortality. This high venous thromboembolism rate justifies the consideration of thromboprophylaxis in this patient group.

Publisher

BMJ

Reference37 articles.

1. Cancer Research UK . Ovarian cancer statistics. 2023. Available: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#:~:text=Ovarian%20cancer%20incidence&text=In%20females%20in%20the%20UK,UK%20(2016%2D2018) [Accessed 10 May 2023].

2. Incidence of venous thromboembolism in patients with cancer – A cohort study using linked United Kingdom databases

3. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients

4. Late consequences of venous thromboembolism: Measuring quality of life after deep vein thrombosis and pulmonary embolism;Ghanima;Thromb Res,2018

5. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3